The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial
Open Access
- 1 July 2012
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 82 (2) , 235-241
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney diseaseKidney International, 2011
- Erythropoiesis-Stimulating Agents — Time for a ReevaluationNew England Journal of Medicine, 2010
- Special Article: The Normal Hematocrit Cardiac Trial RevisitedSeminars in Dialysis, 2009
- Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemiaKidney International, 2009
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney International, 2006
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Effects of Early and Late Intervention with Epoetin α on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4)Journal of the American Society of Nephrology, 2004
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990